マーケットレポート詳細
ドライアイ治療の世界市場：2031年予測
Dry Eye Disease Market (Product: Artificial Tears, Anti-inflammatory Drugs, Cyclosporine, Corticosteroids, Lifitegrast, Punctal Plugs, Secretagogue, and Others) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2023-2031
- 出版元：Transparency Market Research
出版元について - 発行年：2023年12月
- 定価 ：Single User License(1名様ライセンス)US$5,795(米国ドル)/Multi User License(5名様)$8,795 /Enterprise License $11,705
- ご予算に応じた各種ご提案も承ります。詳細はお問い合わせください。
- ご請求は円換算（お見積り日TTSレート）となります。
- 納品形態：PDF by Email
- 当調査レポートは英文201ページになります。
- 商品コード：TMR157
お問い合わせ、お見積りのリクエストは下のボタンをクリックしてご入力ください。
【レポート紹介】
ドライアイ治療の世界市場規模は2022年で61億ドル、2031年に87億ドル、市場の平均年成長率は4.2%になると予測されています。
当レポートでは、ドライアイ治療の市場予測-2031年、各種セグメント別市場分析(製品別、流通経路別、国地域別)、パイプライン分析、市場シェア分析、主要企業プロフィールなどの情報を盛り込み、概略以下の構成でお届けいたします。
【レポート構成概要】
■ドライアイ治療の世界市場予測2017-2031年
・市場規模(US$)
■製品別、市場-2031年
人工涙液
抗炎症薬
シクロスポリン
副腎皮質ステロイド
リフィテグラスト
パンクタルプラグ
分泌促進剤
その他
※(市場規模US$)
■流通経路別、市場-2031年
病院薬局
個人薬局/ドラッグストア
オンライン薬局
※(市場規模US$)
■主要国地域別市場-2031年
北米
・米国、カナダ
欧州
・ドイツ、英国、フランス
・イタリア、スペイン
・その他欧州
アジア太平洋
・日本、中国、インド
・オーストラリア/ニュージーランド
・その他アジア太平洋
中南米
・ブラジル、メキシコ
・その中南米
中東アフリカ
・GCC諸国、南アフリカ
・その他中東アフリカ
※地域別に各種セグメント別の細分化データ掲載、詳細は目次参照
■市場分析
市場ダイナミクス（促進要因、障壁、機会）
パイプライン分析
COVID-19の影響分析
競合状況
市場シェア分析
SWOT分析
■ドライアイ治療の主要企業プロフィール動向
Santen Pharmaceutical Co., Ltd.
Novartis AG
Bausch Health Companies Inc.
Allergan plc
Shire plc
TRB Chemedica International SA
Sun Pharmaceutical Industries Ltd.
千寿製薬株式会社
Sentiss Pharma Pvt. Ltd.
Johnson & Johnson
大塚製薬株式会社
Mitotech S.A.
FCI
（全201頁）
【レポート詳細目次、データ項目一覧は当ページ下を参照ください】
Table of Contents (英文詳細目次）
1. Executive Summary
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Global Dry Eye Disease Market
4. Market Overview
4.1. Market Segmentation
4.1.1. Segment Definition
4.1.2. Industry Evolution / Developments
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Global Dry Eye Disease Market Analysis and Forecast, 2017-2031
5. Key Insights
5.1. Pipeline Analysis
5.2. Disease Prevalence & Incidence Rate Globally With Key Countries
5.3. COVID-19 Pandemic Impact on Industry
6. Dry Eye Disease Market Analysis and Forecast, by Product
6.1. Introduction and Definitions
6.2. Key Findings/Developments
6.3. Market Value Forecast, by Product, 2017–2031
6.3.1. Artificial Tears
6.3.2. Anti-inflammatory Drugs
6.3.3. Cyclosporine
6.3.4. Corticosteroids
6.3.5. Lifitegrast
6.3.6. Punctal Plugs
6.3.7. Secretagogue
6.3.8. Others
6.4. Market Attractiveness, by Product
7. Global Dry Eye Disease Market Analysis and Forecast, by Distribution Channel
7.1. Introduction and Definitions
7.2. Key Findings/Developments
7.3. Market Value Forecast, by Distribution Channel, 2017–2031
7.3.1. Hospital Pharmacies
7.3.2. Independent Pharmacies & Drug Stores
7.3.3. Online Pharmacies
7.4. Market Attractiveness, by Distribution Channel
8. Global Dry Eye Disease Market Analysis and Forecast, by Region
8.1. Key Findings
8.2. Market Value Forecast, by Region, 2017–2031
8.2.1. North America
8.2.2. Europe
8.2.3. Asia Pacific
8.2.4. Latin America
8.2.5. Middle East & Africa
8.3. Market Attractiveness, by Region
9. North America Dry Eye Disease Market Analysis and Forecast
9.1. Introduction
9.1.1. Key Findings
9.2. Market Value Forecast, by Product, 2017–2031
9.2.1. Artificial Tears
9.2.2. Anti-inflammatory Drugs
9.2.3. Cyclosporine
9.2.4. Corticosteroids
9.2.5. Lifitegrast
9.2.6. Punctal Plugs
9.2.7. Secretagogue
9.2.8. Others
9.3. Market Value Forecast, by Distribution Channel, 2017–2031
9.3.1. Hospital Pharmacies
9.3.2. Independent Pharmacies & Drug Stores
9.3.3. Online Pharmacies
9.4. Market Value Forecast, by Country, 2017–2031
9.4.1. U.S.
9.4.2. Canada
9.5. Market Attractiveness Analysis
9.5.1. By Product
9.5.2. By Distribution Channel
9.5.3. By Country
10. Europe Dry Eye Disease Market Analysis and Forecast
10.1. Introduction
10.1.1. Key Findings
10.2. Market Value Forecast, by Product, 2017–2031
10.2.1. Artificial Tears
10.2.2. Anti-inflammatory Drugs
10.2.3. Cyclosporine
10.2.4. Corticosteroids
10.2.5. Lifitegrast
10.2.6. Punctal Plugs
10.2.7. Secretagogue
10.2.8. Others
10.3. Market Value Forecast, by Distribution Channel, 2017–2031
10.3.1. Hospital Pharmacies
10.3.2. Independent Pharmacies & Drug Stores
10.3.3. Online Pharmacies
10.4. Market Value Forecast, by Country/Sub-region, 2017–2031
10.4.1. Germany
10.4.2. U.K.
10.4.3. France
10.4.4. Italy
10.4.5. Spain
10.4.6. Rest of Europe
10.5. Market Attractiveness Analysis
10.5.1. By Product
10.5.2. By Distribution Channel
10.5.3. By Country/Sub-region
11. Asia Pacific Dry Eye Disease Market Analysis and Forecast
11.1. Introduction
11.1.1. Key Findings
11.2. Market Value Forecast, by Product, 2017–2031
11.2.1. Artificial Tears
11.2.2. Anti-inflammatory Drugs
11.2.3. Cyclosporine
11.2.4. Corticosteroids
11.2.5. Lifitegrast
11.2.6. Punctal Plugs
11.2.7. Secretagogue
11.2.8. Others
11.3. Market Value Forecast, by Distribution Channel, 2017–2031
11.3.1. Hospital Pharmacies
11.3.2. Independent Pharmacies & Drug Stores
11.3.3. Online Pharmacies
11.4. Market Value Forecast, by Country/Sub-region, 2017–2031
11.4.1. China
11.4.2. Japan
11.4.3. India
11.4.4. Australia & New Zealand
11.4.5. Rest of Asia Pacific
11.5. Market Attractiveness Analysis
11.5.1. By Product
11.5.2. By Distribution Channel
11.5.3. By Country/Sub-region
12. Latin America Dry Eye Disease Market Analysis and Forecast
12.1. Introduction
12.1.1. Key Findings
12.2. Market Value Forecast, by Product, 2017–2031
12.2.1. Artificial Tears
12.2.2. Anti-inflammatory Drugs
12.2.3. Cyclosporine
12.2.4. Corticosteroids
12.2.5. Lifitegrast
12.2.6. Punctal Plugs
12.2.7. Secretagogue
12.2.8. Others
12.3. Market Value Forecast, by Distribution Channel, 2017–2031
12.3.1. Hospital Pharmacies
12.3.2. Independent Pharmacies & Drug Stores
12.3.3. Online Pharmacies
12.4. Market Value Forecast, by Country/Sub-region, 2017–2031
12.4.1. Brazil
12.4.2. Mexico
12.4.3. Rest of Latin America
12.5. Market Attractiveness Analysis
12.5.1. By Product
12.5.2. By Distribution Channel
12.5.3. By Country/Sub-region
13. Middle East & Africa Dry Eye Disease Market Analysis and Forecast
13.1. Introduction
13.1.1. Key Findings
13.2. Market Value Forecast, by Product, 2017–2031
13.2.1. Artificial Tears
13.2.2. Anti-inflammatory Drugs
13.2.3. Cyclosporine
13.2.4. Corticosteroids
13.2.5. Lifitegrast
13.2.6. Punctal Plugs
13.2.7. Secretagogue
13.2.8. Others
13.3. Market Value Forecast, by Distribution Channel, 2017–2031
13.3.1. Hospital Pharmacies
13.3.2. Independent Pharmacies & Drug Stores
13.3.3. Online Pharmacies
13.4. Market Value Forecast, by Country/Sub-region, 2017–2031
13.4.1. GCC Countries
13.4.2. South Africa
13.4.3. Rest of Middle East & Africa
13.5. Market Attractiveness Analysis
13.5.1. By Product
13.5.2. By Distribution Channel
13.5.3. By Country/Sub-region
14. Competition Landscape
14.1. Market Player - Competition Matrix (By Tier and Size of Companies)
14.2. Market Share Analysis, by Company (2022)
14.3. Company Profiles
14.3.1. Santen Pharmaceutical Co., Ltd.
14.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.1.2. Product Portfolio
14.3.1.3. Financial Overview
14.3.1.4. SWOT Analysis
14.3.1.5. Strategic Overview
14.3.2. Novartis AG
14.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.2.2. Product Portfolio
14.3.2.3. Financial Overview
14.3.2.4. SWOT Analysis
14.3.2.5. Strategic Overview
14.3.3. Bausch Health Companies Inc.
14.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.3.2. Product Portfolio
14.3.3.3. Financial Overview
14.3.3.4. SWOT Analysis
14.3.3.5. Strategic Overview
14.3.4. Allergan plc
14.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.4.2. Product Portfolio
14.3.4.3. Financial Overview
14.3.4.4. SWOT Analysis
14.3.4.5. Strategic Overview
14.3.5. Shire plc
14.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.5.2. Product Portfolio
14.3.5.3. Financial Overview
14.3.5.4. SWOT Analysis
14.3.5.5. Strategic Overview
14.3.6. TRB Chemedica International SA
14.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.6.2. Product Portfolio
14.3.6.3. Financial Overview
14.3.6.4. SWOT Analysis
14.3.6.5. Strategic Overview
14.3.7. Sun Pharmaceutical Industries Ltd.
14.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.7.2. Product Portfolio
14.3.7.3. Financial Overview
14.3.7.4. SWOT Analysis
14.3.7.5. Strategic Overview
14.3.8. Senju Pharmaceutical Co., Ltd.
14.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.8.2. Product Portfolio
14.3.8.3. Financial Overview
14.3.8.4. SWOT Analysis
14.3.8.5. Strategic Overview
14.3.9. Sentiss Pharma Pvt. Ltd.
14.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.9.2. Product Portfolio
14.3.9.3. Financial Overview
14.3.9.4. SWOT Analysis
14.3.9.5. Strategic Overview
14.3.10. Johnson & Johnson
14.3.10.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.10.2. Product Portfolio
14.3.10.3. Financial Overview
14.3.10.4. SWOT Analysis
14.3.10.5. Strategic Overview
14.3.11. Otsuka Pharmaceutical Co., Ltd.
14.3.11.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.11.2. Product Portfolio
14.3.11.3. Financial Overview
14.3.11.4. SWOT Analysis
14.3.11.5. Strategic Overview
14.3.12. Mitotech S.A.
14.3.12.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.12.2. Product Portfolio
14.3.12.3. Financial Overview
14.3.12.4. SWOT Analysis
14.3.12.5. Strategic Overview
14.3.13. FCI
14.3.13.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.13.2. Product Portfolio
14.3.13.3. Financial Overview
14.3.13.4. SWOT Analysis
14.3.13.5. Strategic Overview
List of Tables
Table 01: Global Dry Eye Disease Market Value (US$ Mn) Forecast, by Application, 2017–2031
Table 02: Global Dry Eye Disease Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031
Table 03: Global Dry Eye Disease Market Value (US$ Mn) Forecast, by Region, 2017–2031
Table 04: North America Dry Eye Disease Market Value (US$ Mn) Forecast, by Application, 2017–2031
Table 05: North America Dry Eye Disease Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031
Table 06: North America Dry Eye Disease Market Value (US$ Mn) Forecast, by Country, 2017–2031
Table 07: Europe Dry Eye Disease Market Value (US$ Mn) Forecast, by Application, 2017–2031
Table 08: Europe Dry Eye Disease Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031
Table 09: Europe Dry Eye Disease Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031
Table 10: Asia Pacific Dry Eye Disease Market Value (US$ Mn) Forecast, by Application, 2017–2031
Table 11: Asia Pacific Dry Eye Disease Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031
Table 12: Asia Pacific Dry Eye Disease Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031
Table 13: Latin America Dry Eye Disease Market Value (US$ Mn) Forecast, by Application, 2017–2031
Table 14: Latin America Dry Eye Disease Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031
Table 15: Latin America Dry Eye Disease Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031
Table 16: Middle East & Africa Dry Eye Disease Market Value (US$ Mn) Forecast, by Application, 2017–2031
Table 17: Middle East & Africa Dry Eye Disease Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031
Table 18: Middle East & Africa Dry Eye Disease Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031
List of Figures
Figure 01: Global Dry Eye Disease Market Value (US$ Mn) Forecast, 2017–2031
Figure 02: Global Dry Eye Disease Market Value Share Analysis, by Application 2022 and 2031
Figure 03: Global Dry Eye Disease Market Attractiveness Analysis, by Application, 2023–2031
Figure 04: Global Dry Eye Disease Market Value Share Analysis, by Distribution Channel, 2022 and 2031
Figure 05: Global Dry Eye Disease Market Attractiveness Analysis, by Distribution Channel, 2023–2031
Figure 06: Global Dry Eye Disease Market Value Share Analysis, by Region, 2022 and 2031
Figure 07: Global Dry Eye Disease Market Attractiveness Analysis, by Region, 2023–2031
Figure 08: North America Dry Eye Disease Market Value (US$ Mn) Forecast, 2017–2031
Figure 09: North America Dry Eye Disease Market Value Share Analysis, by Application, 2022 and 2031
Figure 10: North America Dry Eye Disease Market Attractiveness Analysis, by Application, 2023–2031
Figure 11: North America Dry Eye Disease Market Value Share Analysis, by Distribution Channel, 2022 and 2031
Figure 12: North America Dry Eye Disease Market Attractiveness Analysis, by Distribution Channel, 2023–2031
Figure 13: North America Dry Eye Disease Market Value Share Analysis, by Country, 2022 and 2031
Figure 14: North America Dry Eye Disease Market Attractiveness Analysis, by Country, 2023–2031
Figure 15: Europe Dry Eye Disease Market Value (US$ Mn) Forecast, 2017–2031
Figure 16: Europe Dry Eye Disease Market Value Share Analysis, by Application, 2022 and 2031
Figure 17: Europe Dry Eye Disease Market Attractiveness Analysis, by Application, 2023–2031
Figure 18: Europe Dry Eye Disease Market Value Share Analysis, by Distribution Channel, 2022 and 2031
Figure 19: Europe Dry Eye Disease Market Attractiveness Analysis, by Distribution Channel, 2023–2031
Figure 20: Europe Dry Eye Disease Market Value Share Analysis, by Country/Sub-region, 2022 and 2031
Figure 21: Europe Dry Eye Disease Market Attractiveness Analysis, by Country/Sub-region, 2023–2031
Figure 22: Asia Pacific Dry Eye Disease Market Value (US$ Mn) Forecast, 2017–2031
Figure 23: Asia Pacific Dry Eye Disease Market Value Share Analysis, by Application 2022 and 2031
Figure 24: Asia Pacific Dry Eye Disease Market Attractiveness Analysis, by Application, 2023–2031
Figure 25: Asia Pacific Dry Eye Disease Market Value Share Analysis, by Distribution Channel, 2022 and 2031
Figure 26: Asia Pacific Dry Eye Disease Market Attractiveness Analysis, by Distribution Channel, 2023–2031
Figure 27: Asia Pacific Dry Eye Disease Market Value Share Analysis, by Country/Sub-region, 2022 and 2031
Figure 28: Asia Pacific Dry Eye Disease Market Attractiveness Analysis, by Country/Sub-region, 2023–2031
Figure 29: Latin America Dry Eye Disease Market Value (US$ Mn) Forecast, 2017–2031
Figure 30: Latin America Dry Eye Disease Market Value Share Analysis, by Application, 2022 and 2031
Figure 31: Latin America Dry Eye Disease Market Attractiveness Analysis, by Application, 2023–2031
Figure 32: Latin America Dry Eye Disease Market Value Share Analysis, by Distribution Channel, 2022 and 2031
Figure 33: Latin America Dry Eye Disease Market Attractiveness Analysis, by Distribution Channel, 2023–2031
Figure 34: Latin America Dry Eye Disease Market Value Share Analysis, by Country/Sub-region, 2022 and 2031
Figure 35: Latin America Dry Eye Disease Market Attractiveness Analysis, by Country/Sub-region, 2023–2031
Figure 36: Middle East & Africa Dry Eye Disease Market Value (US$ Mn) Forecast, 2017–2031
Figure 37: Middle East & Africa Dry Eye Disease Market Value Share Analysis, by Application, 2022 and 2031
Figure 38: Middle East & Africa Dry Eye Disease Market Attractiveness Analysis, by Application, 2023–2031
Figure 39: Middle East & Africa Dry Eye Disease Market Value Share Analysis, by Distribution Channel, 2022 and 2031
Figure 40: Middle East & Africa Dry Eye Disease Market Attractiveness Analysis, by Distribution Channel, 2023–2031
Figure 41: Middle East & Africa Dry Eye Disease Market Value Share Analysis, by Country/Sub-region, 2022 and 2031
Figure 42: Middle East & Africa Dry Eye Disease Market Attractiveness Analysis, by Country/Sub-region, 2023–2031
Figure 43: Global Dry Eye Disease Market Share Analysis, by Company, 2022